| 產(chǎn)品名稱 | CP 690550 - Tasocitinib | Tofacitinib |
| 產(chǎn)品貨號(hào) | Axon 1338 CAS [477600-75-2] MF C16H20N6OMW 312.37 Purity: 99% Soluble in 0.1N HCl(aq) and DMSO Description Janus Kinase 3 (JAK3) inhibitor; an immunosuppressive agent exhibiting potent effects in preclinical transplantation and arthritis models; clinically safe and effective in preventing transplant rejection and improving symptoms of rheumatoid arthritis and psoriasis.This product is also available as its citrate salt form, Tofacitinib citrate (Axon 2072).? KEYWORDS: CP 690550 | supplier | JAK3 inhibitor | Tasocitinib | Tofacitinib | CP690550 | CP-690550 | CAS [477600-75-2] | JAK-STAT Pathway | JAK | Janus Kinase | immunosuppressive | transplantation | rheumatoid | arthritis | rejection | psoriasis |
| 產(chǎn)品價(jià)格 | 現(xiàn)貨詢價(jià)，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
CP 690550 - Tasocitinib | TofacitinibAxon 1338 CAS [477600-75-2] MF C16H20N6O
DescriptionJanus Kinase 3 (JAK3) inhibitor; an immunosuppressive agent exhibiting potent effects in preclinical transplantation and arthritis models; clinically safe and effective in preventing transplant rejection and improving symptoms of rheumatoid arthritis and psoriasis. KEYWORDS: CP 690550 | supplier | JAK3 inhibitor | Tasocitinib | Tofacitinib | CP690550 | CP-690550 | CAS [477600-75-2] | JAK-STAT Pathway | JAK | Janus Kinase | immunosuppressive | transplantation | rheumatoid | arthritis | rejection | psoriasis ? List of publications using CP 690550 (Axon 1338) purchased from Axon Medchem
JAK3 inhibitor
Chemical name3-{(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile Source informationPfizer compound; Sold for research purposes under agreement from Pfizer Inc.Parent CAS No.[477600-75-2] |
| 產(chǎn)品資料 |
